Emergent BioSolutions Inc.

Emergent BioSolutions (acquirer of Cangene bioPharma) provides contract manufacturing services for both bulk drug substances and finished drug products. Emergent's state-of-the-art single-use BDS facility enables turnkey upstream and downstream support for microbial, mammalian and viral cell lines. Emergent's Fill/Finish service offering includes vials and syringes, for both liquid and lyophilized products (including lyo cycle development). Emergent's manufacturing facilities (located in Baltimore, MD) currently produce 20 commercial products and supported over 200 clinical drug products. For more information, visit www.emergentcontractmanufacturing.com


Contact details

1111 S. Paca Street
United States